Medtronic plc logo
Medtronic plc (MDT)
Compare

Medtronic plc (MDT) EBITDA Margin: 26.97%

Is Medtronic plc’s EBITDA margin high or low?

Medtronic plc's EBITDA margin of 26.97% is in line with its 5-year average of 26.72%, around the middle of its 5-year range (24.98%–27.85%).

As of Wednesday, June 17, 2026. 0.95% below its 12-month average of 27.23%.

MDT EBITDA Margin Chart

MDT EBITDA Margin
26.97%-1.89% 1Y
Zoom

MDT Average EBITDA Margin Chart

MDT Current vs Average EBITDA Margin Chart

MDT EBITDA Margin Metrics

EBITDA MARGIN

26.97%

EBITDA MARGIN AVG TTM

27.23%

EBITDA MARGIN AVG 3Y

26.91%

EBITDA MARGIN AVG 5Y

26.72%

EBITDA MARGIN AVG 10Y

28.00%

EBITDA MARGIN AVG 15Y

28.79%

EBITDA MARGIN AVG 20Y

29.42%

CURRENT VS TTM AVG

-0.95%

CURRENT VS 3Y AVG

+0.20%

CURRENT VS 5Y AVG

+0.92%

CURRENT VS 10Y AVG

-3.68%

CURRENT VS 15Y AVG

-6.32%

CURRENT VS 20Y AVG

-8.32%

MDT Competitors' EBITDA Margin

NAMEMARKET CAPEBITDA MARGINTTM3Y5Y
Medtronic plc (MDT)$103.29B26.97%27.23%26.91%26.72%
Bristol-Myers Squibb Company (BMY)vs ›$114.19B30.18%18.37%30.35%29.39%
Vertex Pharmaceuticals Incorporated (VRTX)vs ›$115.02B40.28%22.34%35.25%38.74%
HCA Healthcare, Inc. (HCA)vs ›$88.05B20.64%20.16%20.49%20.85%
Stryker Corporation (SYK)vs ›$119.06B25.14%23.50%23.36%22.67%
Elevance Health Inc. (ELV)vs ›$85.70B4.85%5.39%5.84%6.22%
CVS Health Corporation (CVS)vs ›$127.73B2.45%3.06%3.76%4.57%
Danaher Corporation (DHR)vs ›$128.06B28.27%29.38%31.44%31.51%
Cigna Corporation (CI)vs ›$76.25B4.22%4.42%5.04%5.39%
Boston Scientific Corporation (BSX)vs ›$69.74B25.42%24.47%23.70%21.87%

Margin Comparison

Gross Margin

65.0%

EBITDA Margin

27.0%

Operating Margin

17.8%

Net Margin

13.2%

Formula: EBITDA Margin = (EBITDA / Revenue) × 100

Why EBITDA Margin matters:

  • Removes effects of depreciation policies (D&A)
  • Capital structure neutral (ignores interest)
  • Tax neutral (ignores tax differences)
  • Good proxy for operating cash generation

Medtronic plc EBITDA Margin Formula & Definition

EBITDA Margin = EBITDA / Revenue

EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Medtronic plc EBITDA Margin FAQ

What is the EBITDA margin for Medtronic plc (MDT)?
The EBITDA margin for MDT stock is 26.97%.
Is Medtronic plc's EBITDA margin high or low?
Medtronic plc's EBITDA margin of 26.97% is in line with its 5-year average of 26.72%, around the middle of its 5-year range (24.98%–27.85%).
What is the TTM average EBITDA margin for Medtronic plc (MDT)?
The TTM average EBITDA margin for MDT stock is 27.23%.
What is the 3Y average EBITDA margin for Medtronic plc (MDT)?
The 3Y average EBITDA margin for MDT stock is 26.91%.
What is the 5Y average EBITDA margin for Medtronic plc (MDT)?
The 5Y average EBITDA margin for MDT stock is 26.72%.
What is the 10Y average EBITDA margin for Medtronic plc (MDT)?
The 10Y average EBITDA margin for MDT stock is 28.00%.
What is the 15Y average EBITDA margin for Medtronic plc (MDT)?
The 15Y average EBITDA margin for MDT stock is 28.79%.
What is the 20Y average EBITDA margin for Medtronic plc (MDT)?
The 20Y average EBITDA margin for MDT stock is 29.42%.

Medtronic plc EBITDA Margin History

DATEEBITDA MARGIN
2026-04-2426.97%
2025-04-3027.49%
2024-04-3025.35%
2023-04-3027.85%
2022-04-3027.70%
2021-04-3024.98%
2020-04-3027.01%
2019-04-3030.43%
2018-04-3031.60%
2017-04-3028.99%
2016-04-3029.63%
2015-04-3026.94%
2014-04-3029.01%
2013-04-3032.90%
2012-04-3032.92%
2011-04-3030.87%
2010-04-3032.36%
2009-04-3024.04%
2008-04-3027.95%
2007-04-3035.14%
2006-04-3037.63%
2005-04-3038.86%
2004-04-3039.88%
2003-04-3039.94%
2002-04-3038.67%
2001-04-3039.19%
2000-04-3038.44%
1999-04-3038.21%
1998-04-3048.30%
1997-04-3042.87%

About Medtronic plc

Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.

Galway
95,000 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Geoffrey Straub Martha